Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Cancer(2024)10.1002/cncr.35323Source: DataRank Database

Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study is a research paper published in Cancer (2024). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 7.85)OA: hybridTopics (84)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (45)

Eva Blondeaux ORCID,Chiara Molinelli ORCID,Raphaëlle Bas,Hee Jeong Kim ORCID,Antonio Di Meglio ORCID

Live enrichment

PubMed:38752572 OpenAlex:https://openalex.org/W4396976588

Associazione Italiana per la Ricerca sul Cancro

Grant: MFAG 2020 ID 24698

National Health and Medical Research Council (NHMRC)

Grant: 145684

Clinical Outcomes In Individuals With An Inherited Predisposition To Breast Cancer

National Health and Medical Research Council (NHMRC)

Grant: 288704

Risk factors, screening, prophylaxis and outcomes in individuals from breast cancer families: kConFab Follow-Up Study

National Health and Medical Research Council (NHMRC)

Grant: 454508

kConFab Follow-Up Project: A Prospective Study of Non-Genetic Risk Modifiers in Women at High Risk for Breast Cancer

FWCI

7.85

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.35323

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.35323

publisherhttps://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.35323

journalhttps://doi.org/10.1002/cncr.35323

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38752572

Fields of Study

BRCA gene mutations in cancerBreast Cancer Treatment StudiesHER2/EGFR in Cancer Research03 medical and health sciences0302 clinical medicineAdultFemaleHumansYoung AdultBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsDisease-Free SurvivalGerm-Line MutationPrognosisErb-b2 Receptor Tyrosine KinasesRetrospective StudiesCohort StudiesInternationality

MeSH Terms

AdultBreast NeoplasmsFemaleHumansPrognosisRetrospective StudiesCohort StudiesGerm-Line MutationDisease-Free SurvivalReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesBRCA1 ProteinBRCA2 ProteinInternationalityYoung Adult

Keywords

MedicineBreast cancerOncologyHazard ratioInternal medicineRetrospective cohort studyProportional hazards modelGynecologyHormone receptorCancerCohortLogistic regressionPopulationConfidence intervalAdultInternationalityReceptor, ErbB-2BRCA610Breast NeoplasmsEstudios RetrospectivosSupervivencia sin EnfermedadErb-b2 Receptor Tyrosine Kinasesbreast cancer; Brca; her2Disease-Free SurvivalCohort StudiesYoung AdultReceptor ErbB-2Proteína BRCA2HumansProteína BRCA1Germ-Line MutationRetrospective StudiesBRCA2 Proteinyoung womenAdultoBRCA1 ProteinsubtypesPronósticoFemeninoNeoplasias de la MamaBRCA; HER2‐low; breast cancer; subtypes; young womenAdulto JovenPrognosisHumanosBRCA; breast cancer; HER2-low; subtypes; young women;BRCA; breast cancer; HER2-low; subtypes; young womenMutación de Línea GerminalFemaleHER2‐low

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being